HRT Dose Calculator- Free Hormone Replacement Therapy Dose Conversion and Equivalence Tool

About This HRT Dose Calculator

This HRT Dose Calculator is designed for menopausal women, perimenopausal women, women with premature ovarian insufficiency, and healthcare providers who need to understand approximate dose equivalences between different estrogen formulations used in hormone replacement therapy. Whether you are switching from oral estradiol tablets to transdermal patches, comparing EstroGel pump doses to Sandrena gel sachets, or converting between conjugated equine estrogens and bioidentical estradiol, this tool provides instant equivalence calculations based on published clinical pharmacokinetic data.

The calculator uses dose conversion factors derived from clinical guidelines published by the International Menopause Society, North American Menopause Society, British Menopause Society, and pharmacokinetic studies comparing bioavailability across different routes of administration. It classifies doses into four clinical categories (ultra-low, low, standard, and high) based on oral estradiol equivalence, and calculates appropriate micronized progesterone doses for endometrial protection in women with an intact uterus, following both sequential and continuous combined regimen protocols.

The comparison table displays all six major estrogen formulations simultaneously with their equivalent doses, route classification, dose level indicators, and practical application instructions. The progesterone section provides recommendations for micronized progesterone (preferred), medroxyprogesterone acetate, norethindrone acetate, dydrogesterone, and the levonorgestrel intrauterine system. The route safety guide compares oral and transdermal estrogen across key clinical parameters to help inform discussions with healthcare providers about the most appropriate delivery method.

Understanding Hormone Replacement Therapy Dosing: A Complete Guide to HRT Formulations, Equivalences, and Clinical Considerations

Hormone replacement therapy (HRT), also known as menopausal hormone therapy (MHT), is the most effective treatment for managing moderate to severe vasomotor symptoms associated with menopause, including hot flashes, night sweats, sleep disturbance, and genitourinary syndrome of menopause. With recent updates from the FDA in 2025 removing the longstanding black box warning from HRT products, there is renewed interest in understanding optimal dosing strategies, formulation equivalences, and individualized treatment approaches. This comprehensive guide explores the clinical science behind HRT dosing, helping patients and healthcare providers navigate the complex landscape of estrogen and progesterone therapy.

What Is Hormone Replacement Therapy and Why Does Dosing Matter?

Hormone replacement therapy replenishes the ovarian hormones that diminish during the natural menopausal transition. The primary goal is to alleviate symptoms caused by declining estrogen and progesterone levels, which typically begin during perimenopause and intensify after menopause. The two main components of HRT are estrogen therapy (ET) for women who have had a hysterectomy, and combined estrogen-progesterone therapy (EPT) for women with an intact uterus. The addition of progesterone is essential to prevent endometrial hyperplasia and reduce the risk of endometrial cancer that can occur with unopposed estrogen exposure.

Dosing matters enormously in HRT because the therapeutic goal is to use the lowest effective dose for the shortest duration necessary to control symptoms. Underdosing leads to persistent symptoms and reduced quality of life, while excessive dosing increases the risk of adverse effects including venous thromboembolism, stroke, and hormone-sensitive cancers. The concept of dose equivalence across different formulations and routes of administration is critical, as switching between oral tablets, transdermal patches, gels, sprays, and other delivery systems requires an understanding of comparative bioavailability and pharmacokinetics.

Estrogen Formulations and Standard Dosing Ranges

Several estrogen formulations are approved for menopausal hormone therapy, each with distinct pharmacokinetic properties. The most commonly prescribed estrogens include 17-beta estradiol (bioidentical), conjugated equine estrogens (CEE), ethinyl estradiol, and synthetic conjugated estrogens. The choice of formulation depends on clinical goals, patient preference, risk factors, and route of administration.

Oral estradiol is typically dosed from 0.5 mg to 2 mg daily. The standard starting dose is 1 mg per day for moderate to severe vasomotor symptoms, with lower doses of 0.5 mg considered for initial therapy or for women with milder symptoms. Conjugated equine estrogens (CEE) are dosed from 0.3 mg to 1.25 mg daily, with 0.625 mg being the standard dose. Oral estradiol valerate is dosed slightly higher than micronized estradiol due to molecular weight differences, with approximately 2 mg of estradiol valerate being equivalent to 1.5 mg of micronized estradiol.

Transdermal estradiol patches deliver a continuous dose measured in micrograms per 24 hours. Available strengths typically range from 14 mcg to 100 mcg per day, with 25 to 50 mcg being standard starting doses. Patches are changed either once or twice weekly depending on the brand and formulation. The transdermal route avoids first-pass hepatic metabolism, which means it does not increase hepatic protein production to the same extent as oral estrogen, resulting in a lower risk of venous thromboembolism and a more physiological estradiol-to-estrone ratio.

Transdermal Gels, Sprays, and Other Delivery Systems

Transdermal estradiol gels represent another important delivery option. EstroGel delivers 0.75 mg of estradiol per pump application (1.25 g of gel), while Divigel comes in sachets of 0.25 mg, 0.5 mg, and 1.0 mg. Sandrena gel contains 0.1% estradiol and is available in 0.5 mg and 1.0 mg sachets. Elestrin delivers 0.52 mg of estradiol per pump (0.87 g of gel). The absorption of gel formulations can vary depending on application site, skin condition, and environmental factors such as heat and humidity.

Estradiol spray (Lenzetto/Evamist) delivers 1.53 mg per spray, with the typical starting dose being one spray daily applied to the inner forearm. The dose can be increased to two or three sprays based on clinical response. Like other transdermal formulations, sprays avoid first-pass metabolism and provide relatively stable estradiol levels throughout the day.

Vaginal estrogen formulations are primarily used for genitourinary syndrome of menopause (GSM) rather than systemic symptom relief. Low-dose vaginal estrogen in the form of tablets, creams, inserts, or rings delivers minimal systemic absorption and is generally considered safe even in women where systemic HRT might be contraindicated. The vaginal ring (Estring) delivers 7.5 mcg per day of estradiol locally, while Femring delivers systemic doses of 50 or 100 mcg per day.

Progesterone and Progestogen Dosing for Endometrial Protection

Women with an intact uterus who take systemic estrogen therapy require progesterone or a progestogen for endometrial protection. Unopposed estrogen increases the risk of endometrial hyperplasia from approximately 3% to 64% over time. The type, dose, and duration of progestogen therapy must be carefully matched to the estrogen dose being used.

Micronized progesterone (bioidentical) is the preferred progestogen for most women due to its favorable safety profile compared to synthetic progestins. For sequential (cyclical) regimens, the standard dose is 200 mg orally at bedtime for 12 to 14 days per 28-day cycle. For continuous combined regimens, 100 mg daily is typically used. When higher estrogen doses are prescribed, the progesterone dose may need to be increased accordingly, such as 300 mg for 12 days in cyclical regimens or 200 mg daily in continuous regimens.

Medroxyprogesterone acetate (MPA) is dosed at 5 to 10 mg daily for 10 to 14 days per month in sequential regimens, or 2.5 mg daily in continuous combined regimens. Norethindrone acetate (NETA) is used at 5 mg for 10 to 12 days in sequential regimens, or 0.35 to 1 mg daily in continuous regimens. Dydrogesterone is dosed at 10 mg daily for 12 to 14 days per month in cyclical regimens, or 5 to 10 mg daily in continuous regimens. The levonorgestrel-releasing intrauterine system (LNG-IUS) with 52 mg of levonorgestrel provides endometrial protection for up to 5 years when used alongside estrogen therapy.

Sequential Versus Continuous Combined Regimens

The choice between sequential and continuous combined HRT depends primarily on the woman's menopausal status. Sequential regimens, where progesterone is added for 12 to 14 days each month, are recommended for perimenopausal women and those within the first year of menopause. This approach produces a predictable withdrawal bleed, which can help monitor endometrial health. Continuous combined regimens, where both estrogen and progesterone are taken daily without interruption, are designed for postmenopausal women (typically more than 12 months since last menstrual period) and aim to achieve amenorrhea.

The transition from sequential to continuous combined therapy should generally occur after at least one to two years of sequential HRT. Switching too early increases the likelihood of unpredictable breakthrough bleeding. Long-cycle regimens, where progesterone is given for 14 days every three months rather than monthly, have been explored as an alternative to reduce progestogen exposure, although evidence for their long-term endometrial safety is more limited.

Route of Administration: Oral Versus Transdermal

The route of estrogen administration has significant implications for safety and efficacy. Transdermal estrogen (patches, gels, and sprays) is increasingly recommended as the preferred first-line option by multiple international guidelines, particularly for women with cardiovascular risk factors, obesity, migraine with aura, or a history of venous thromboembolism. Transdermal delivery avoids first-pass hepatic metabolism, which means it does not increase production of clotting factors, C-reactive protein, sex hormone-binding globulin (SHBG), or triglycerides to the same degree as oral estrogen.

When comparing dosages between oral and transdermal routes, a standard oral estradiol dose of 1 mg (1000 mcg) is roughly equivalent to a transdermal patch delivering 50 mcg per day, representing approximately a 20-fold difference in absolute dose. This dramatic difference reflects the high first-pass metabolism that oral estrogen undergoes in the liver, where a substantial portion is converted to estrone (E1) and bound by SHBG before reaching the systemic circulation. Transdermal estrogen maintains a more physiological estradiol-to-estrone ratio (closer to 1:1), compared to the reversed ratio (approximately 1:3-5) seen with oral administration.

Dose Conversion Between Formulations

Converting between different estrogen formulations requires understanding approximate dose equivalences, though it is important to recognize that individual absorption varies significantly. The following approximate equivalences are used clinically as starting points, with subsequent dose adjustments based on symptom response.

For conjugated equine estrogens (CEE), the approximate equivalences to oral estradiol are as follows: CEE 0.3 mg is roughly equivalent to oral estradiol 0.5 mg, CEE 0.45 mg to estradiol 0.75 mg, CEE 0.625 mg to estradiol 1 mg, and CEE 1.25 mg to estradiol 2 mg. However, CEE contains a mixture of estrogens including equilin and its metabolites, making precise dose equivalence with estradiol formulations inherently imprecise.

Timing Hypothesis and the Window of Opportunity

The timing of HRT initiation relative to menopause onset significantly influences the benefit-risk profile. The "timing hypothesis" or "window of opportunity" concept suggests that HRT initiated within 10 years of menopause onset or before age 60 is associated with cardiovascular benefit, while initiation later in life may increase cardiovascular risk. This concept emerged from reanalysis of the Women's Health Initiative (WHI) data and has been supported by subsequent studies including the Danish Osteoporosis Prevention Study (DOPS) and the Early versus Late Intervention Trial with Estradiol (ELITE).

For women within the favorable treatment window, the benefit-risk ratio for HRT is most favorable when treating moderate to severe vasomotor symptoms. The absolute risk of adverse events is very low in healthy women aged 50 to 59 or within 10 years of menopause. This translates to roughly 2 additional cardiovascular events per 10,000 woman-years for combined EPT, and potential cardiovascular benefit with estrogen-only therapy in this age group.

Dose Titration and Clinical Monitoring

The principle of using the lowest effective dose guides HRT management. Treatment typically begins at a low or standard starting dose, with reassessment after 4 to 8 weeks. If symptoms persist, the dose can be increased in increments. Conversely, once symptoms are well-controlled for 6 to 12 months, a gradual dose reduction may be attempted to determine the minimum effective dose.

Routine monitoring of serum estradiol levels is generally not recommended for standard menopausal HRT management, as hormone levels do not reliably correlate with symptom control or treatment safety. Clinical symptom assessment remains the primary guide for dose adjustment. However, serum levels may be useful in specific situations such as premature ovarian insufficiency, non-response to standard doses, or suspected non-absorption of transdermal formulations.

Special Populations and Dose Considerations

Certain populations require special consideration in HRT dosing. Women with premature ovarian insufficiency (POI), defined as menopause before age 40, typically need higher doses of estrogen than those with natural menopause at the average age. Recommendations include transdermal estradiol 100 mcg per day or oral estradiol 2 mg per day, aiming to replicate physiological premenopausal estrogen levels. These women should continue HRT at least until the average age of natural menopause (approximately 51 years).

Women with obesity may require dose adjustments due to altered hormone metabolism. Adipose tissue converts androgens to estrogens, which can affect the clinical picture. Transdermal estrogen is particularly recommended in obese women due to the increased thrombotic risk associated with oral estrogen in this population. Older women or those starting HRT more than 10 years after menopause should begin at the lowest available dose with careful monitoring.

Women with a history of migraine with aura should preferentially use transdermal estrogen to avoid the estrogen fluctuations associated with oral dosing that can trigger migraines. Those with liver disease may also benefit from transdermal delivery, which bypasses hepatic first-pass metabolism. Women with a history of deep vein thrombosis or pulmonary embolism should generally avoid oral estrogen entirely, with transdermal formulations considered on a case-by-case basis with appropriate counseling.

Testosterone in HRT: Indications and Dosing

Testosterone supplementation may be considered for postmenopausal women with hypoactive sexual desire disorder (HSDD) who do not respond to estrogen therapy alone. The recommended approach is percutaneous (transdermal) testosterone, with current guidelines suggesting physiological replacement doses that aim to restore testosterone levels to the premenopausal range.

Typical dosing for women is approximately one-tenth of the male physiological dose. Testosterone patches designed for women (300 mcg/day) have been studied but availability varies by region. Testosterone cream or gel compounded for women typically delivers 5 to 10 mg per day when applied to the skin. Current guidelines recommend limiting testosterone therapy to a maximum of 24 months due to insufficient long-term safety data, with regular monitoring of testosterone levels to avoid supraphysiological dosing.

Non-Hormonal Alternatives and Their Comparative Efficacy

For women who cannot or prefer not to use HRT, several non-hormonal options are available. The selective serotonin reuptake inhibitor (SSRI) paroxetine at 7.5 mg (Brisdelle) is the only non-hormonal therapy specifically FDA-approved for vasomotor symptoms. Other SSRIs and SNRIs including venlafaxine, desvenlafaxine, and escitalopram have shown moderate efficacy in clinical trials. Gabapentin (900 mg/day) and pregabalin (150 mg/day) can reduce hot flash frequency by approximately 50% to 65%. The neurokinin 3 (NK3) receptor antagonist fezolinetant (Veozah) was approved in 2023 and represents a newer mechanism of action specifically targeting the thermoregulatory center in the hypothalamus.

In terms of comparative efficacy, standard-dose HRT reduces vasomotor symptoms by approximately 80% to 90%, while non-hormonal alternatives typically achieve 40% to 65% reduction. Placebo response accounts for approximately 20% to 40% symptom reduction. This substantial efficacy gap underscores why HRT remains the first-line treatment for moderate to severe menopausal symptoms when not contraindicated.

Duration of Treatment and Discontinuation

There is no mandatory maximum duration for HRT use. Current guidelines from the International Menopause Society (IMS), North American Menopause Society (NAMS), and British Menopause Society (BMS) all state that the duration of HRT should be individualized based on the ongoing benefit-risk assessment for each woman. The previous practice of arbitrary time limits (such as limiting use to 5 years) is no longer recommended.

When discontinuation is appropriate, a gradual dose taper over several months is generally preferred over abrupt cessation, as tapering may reduce the likelihood of symptom rebound. A common approach is to reduce the estrogen dose by one step every 3 to 6 months. Approximately 50% of women experience some return of vasomotor symptoms after discontinuing HRT, regardless of the method of discontinuation.

Clinical Safety Considerations by Route and Dose

The safety profile of HRT is significantly influenced by the type of estrogen, route of administration, type of progestogen, and dose used. Transdermal estrogen at doses up to 50 mcg per day has not been associated with an increased risk of venous thromboembolism in observational studies, whereas oral estrogen, particularly at standard and high doses, carries a small but measurable increased risk. The absolute risk remains low in healthy women under 60, estimated at approximately 2 additional VTE events per 10,000 woman-years.

Regarding breast cancer risk, the evidence suggests that estrogen-only therapy for women without a uterus may be associated with a slightly reduced risk over 10 to 20 years of use, while combined estrogen-progestogen therapy carries a small increased risk that becomes apparent after approximately 5 years of use. The type of progestogen matters, with micronized progesterone appearing to carry a lower risk than synthetic progestins like medroxyprogesterone acetate. Using the lowest effective dose of both estrogen and progesterone helps minimize these risks.

Global Application and Population Considerations

HRT dosing guidelines have been developed and validated across diverse global populations, though most pivotal clinical trials were conducted in predominantly North American and European cohorts. The Women's Health Initiative (WHI) enrolled primarily white American women aged 50 to 79, while European studies such as those from Finland, Denmark, and the United Kingdom have provided complementary data using different formulations, particularly estradiol and micronized progesterone rather than the CEE/MPA combination studied in the WHI.

Some evidence suggests that body composition, genetic polymorphisms in estrogen metabolism enzymes, and ethnic background may influence individual responses to HRT. East Asian women may achieve higher serum estradiol levels at equivalent doses compared to Western populations, potentially allowing for lower starting doses. South Asian populations may have different cardiovascular risk profiles that influence the benefit-risk calculation. Healthcare providers worldwide should consider population-specific factors when initiating and adjusting HRT doses, while recognizing that individual variation within any population typically exceeds between-population differences.

Validation Across Diverse Populations

The principles of HRT dosing have been validated across multiple international settings. Major guideline bodies including the International Menopause Society (IMS), North American Menopause Society (NAMS), European Menopause and Andropause Society (EMAS), British Menopause Society (BMS), and Endocrine Society all broadly agree on the fundamental approach of lowest effective dose, transdermal preference for high-risk patients, and individualized treatment duration. Regional variations in available formulations and prescribing practices exist, but the core principles of dose optimization remain consistent worldwide.

Different regions may have different formulations commercially available. Conjugated equine estrogens remain more commonly used in North America, while 17-beta estradiol preparations are more prevalent in Europe and other regions. Some regions have access to formulations not widely available elsewhere, such as estetrol (E4), tibolone, or specific combination products. Healthcare providers should be familiar with the formulations available in their practice setting and their approximate dose equivalences.

Contraindications and When HRT Should Not Be Used

Absolute contraindications to systemic HRT include unexplained vaginal bleeding, active or recent arterial thromboembolic disease (such as heart attack or stroke), active venous thromboembolism, known or suspected breast cancer, known or suspected estrogen-sensitive malignancy, active liver disease with abnormal liver function tests, known thrombophilic disorder (for oral HRT), and porphyria cutanea tarda. Relative contraindications requiring careful individual assessment include a history of endometrial cancer, a history of venous thromboembolism (where transdermal estrogen may be considered), coronary heart disease, and active gallbladder disease.

It is important to note that low-dose vaginal estrogen for genitourinary symptoms is generally considered safe even in many situations where systemic HRT is contraindicated, as systemic absorption is minimal. Each woman's individual risk factors should be assessed comprehensively before initiating therapy, and the decision to use HRT should involve shared decision-making between the patient and her healthcare provider.

Recent Developments: 2025 FDA Label Changes

In late 2025, the FDA announced the removal of the black box warning from menopausal hormone therapy products. This landmark decision reflected the evolving understanding that the risks identified in the WHI trials were specific to certain populations (older women, specific formulations) and did not apply uniformly to all women using HRT. The updated labeling aims to encourage more nuanced conversations between healthcare providers and patients about the individual benefits and risks of therapy, rather than discouraging HRT use through blanket warnings.

The FDA label changes do not alter the fundamental principles of HRT prescribing: use the lowest effective dose, prefer transdermal routes for women with specific risk factors, include adequate progestogen for women with a uterus, and reassess regularly. However, they do represent a significant shift in regulatory stance that may increase both provider willingness to prescribe and patient acceptance of HRT.

How This Calculator Works

This HRT Dose Calculator is designed as an educational reference tool to help users understand approximate dose equivalences between different estrogen formulations and to determine appropriate progesterone doses for endometrial protection. The calculator allows users to select their current or planned estrogen formulation and dose, then displays equivalent doses across other common formulations. It also calculates the recommended progesterone dose based on the estrogen dose level and chosen regimen type (sequential or continuous combined).

The dose equivalences used in this calculator are based on published clinical guidelines and pharmacokinetic studies. They represent approximate starting points for clinical decision-making, not precise bioequivalences. Individual absorption, metabolism, and clinical response vary significantly between patients, and any dosing decisions should be made in consultation with a qualified healthcare provider who can assess individual risk factors and monitor treatment response.

Frequently Asked Questions

Conclusion

Hormone replacement therapy remains the most effective treatment for moderate to severe menopausal symptoms. Understanding dose equivalences between different formulations and routes of administration is essential for optimal prescribing and for empowering patients to participate in shared decision-making about their treatment. The fundamental principles of HRT dosing include starting at the lowest effective dose, preferring transdermal delivery for women with specific risk factors, ensuring adequate progestogen for endometrial protection in women with a uterus, and individualizing treatment duration based on ongoing benefit-risk assessment. With the 2025 FDA label changes reflecting improved understanding of HRT safety, more women than ever can benefit from properly prescribed hormone therapy tailored to their individual needs and circumstances.